BRIDGEWATER, N.J. – Bausch + Lomb, a leading global eye health company, launched LUMIFY™ (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness. In clinical trials, LUMIFY eye drops demonstrated a strong safety and efficacy profile with low risk for rebound redness and 95% symptom improvement seen at one minute and lasting up to eight hours.
"We are excited to make LUMIFY available to the millions of patients who may benefit from fast acting and long lasting redness reduction with a low risk of potential side effects associated with other redness relievers,” said Joseph Gordon, president, Consumer Healthcare and Vision Care, Bausch + Lomb. “We’re proud to provide these innovative eye drops to eye care professionals and their patients who have been looking for a new redness relieving alternative.”
LUMIFY is an alpha-2 (α2)-adrenergic receptor (AR) agonist with a unique method of action that selectively constricts venules, while maintaining the availability of oxygen to surrounding tissue. Six clinical studies were conducted in over 600 patients to evaluate its safety and efficacy, including studies with both pediatric and geriatric subjects. Its efficacy and safety profile includes significant redness reduction for up to eight hours, as well as, a low risk of allergic reactions among all patient groups.